About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Prometheus Biosciences image

Prometheus Biosciences

Rank#1586
Market Cap9.56B
CountryUnited States
Summary
History
References
Summaryarrow
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Historyarrow

Prometheus Biosciences was founded in 2018 by scientists with years of experience in the pharmaceutical, diagnostics and biotechnology industry. Our team of experts have come together to bring innovative solutions to the healthcare industry leveraging cutting-edge technologies across a variety of health areas such as genomics, precision medicine, personalized medicine, and digital health.

Referencesarrow

https://in.investing.com/equities/prometheus-biosciences

https://finance.yahoo.com/quote/RXDX/profile?p=RXDX

https://www.crunchbase.com/organization/prometheus-laboratories

https://sec.report/CIK/0001718852

https://companiesmarketcap.com/

https://www.prometheusbiosciences.com

Share

Leadership team
M
Mr. Mark C. McKenna (Pres, CEO & Chairman)
D
Dr. Keith W. Marshall M.B.A., MBA, Ph.D. (Chief Financial Officer)
M
Mr. Mark Stenhouse (Chief Operating Officer)
Products / Services
Biotechnology, Health Diagnostics, Pharmaceutical, Therapeutics
Number of Employees
50 - 100
Address
San Diego, California, United States
Established
1995-01-01
Company Registration
SEC CIK number: 0001718852
Revenue
5M - 20M
Traded as
RXDX
Website
https://www.prometheusbiosciences.com
Social Media
linkedin
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo